The Journal of Allergy and Clinical Immunology
Volume 123, Issue 4 , Pages 875-882.e1, April 2009

Toll-like receptor 2 is important for the TH1 response to cutaneous sensitization

  • Haoli Jin, MD, PhD

      Affiliations

    • Division of Immunology, Children's Hospital, and the Department of Pediatrics, Harvard Medical School, Boston, Mass
    • These authors contributed equally to this work.
  • ,
  • Lalit Kumar, PhD

      Affiliations

    • Division of Immunology, Children's Hospital, and the Department of Pediatrics, Harvard Medical School, Boston, Mass
    • These authors contributed equally to this work.
  • ,
  • Clinton Mathias, PhD

      Affiliations

    • Division of Immunology, Children's Hospital, and the Department of Pediatrics, Harvard Medical School, Boston, Mass
  • ,
  • David Zurakowski, PhD

      Affiliations

    • Department of Anesthesia and Surgery, Children's Hospital, Boston, Mass
  • ,
  • Hans Oettgen, MD, PhD

      Affiliations

    • Division of Immunology, Children's Hospital, and the Department of Pediatrics, Harvard Medical School, Boston, Mass
  • ,
  • Leonid Gorelik, PhD

      Affiliations

    • Biogen Idec, Inc, Cambridge, Mass
  • ,
  • Raif Geha, MD

      Affiliations

    • Division of Immunology, Children's Hospital, and the Department of Pediatrics, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationReprint requests: Raif Geha, MD, Division of Immunology, Room 10210, Karp Family Research Building, Children's Hospital, One Blackfan Circle, Boston, MA 02115.

Received 20 August 2008; received in revised form 22 January 2009; accepted 4 February 2009.

Background

Atopic dermatitis and allergic contact dermatitis are skin disorders triggered by epicutaneous sensitization with protein antigens and contact sensitization with haptens, respectively. Skin is colonized with bacteria, which are a source of Toll-like receptor (TLR) 2 ligands.

Objective

We sought to examine the role of TLR2 in murine models of atopic dermatitis and allergic contact dermatitis.

Methods

TLR2−/− mice and wild-type littermates were epicutaneously sensitized with ovalbumin (OVA) or contact sensitized with oxazolone (OX). Skin histology was assessed by means of hematoxylin and eosin staining and immunohistochemistry. Ear swelling was measured with a micrometer. Cytokine mRNA expression was examined by means of quantitative RT-PCR. Antibody levels and splenocyte secretion of cytokines in response to OVA stimulation were measured by means of ELISA. Dendritic cells were examined for their ability to polarize T-cell receptor/OVA transgenic naive T cells to TH1 and TH2.

Results

In response to OVA sensitization, TLR2−/− mice experienced skin infiltration with eosinophils and CD4+ cells, as well as upregulation of TH2 cytokine mRNAs that was comparable with that seen in wild-type littermates. In contrast, epidermal thickening, IFN-γ expression in the skin, IFN-γ production by splenocytes, and IgG2a anti-OVA antibody levels were impaired in TLR2−/− mice. After OX ear challenge, contact sensitized TLR2−/− mice exhibited defective ear swelling with impaired cellular infiltration, decreased epidermal thickening and local IFN-γ expression, and impaired OX-specific IgG2a responses. Dendritic cells from TLR2−/− mice induced significantly lower production of IFN-γ but normal IL-4 and IL-13 production in naive T cells.

Conclusions

These results indicate that TLR2 promotes the IFN-γ response to cutaneously introduced antigens.

Key words: Toll-like receptor 2, atopic dermatitis, contact hypersensitivity, oxazolone

Abbreviations used: ACD, Allergic contact dermatitis, AD, Atopic dermatitis, AHR, Airway hyperresponsiveness, DC, Dendritic cell, NF-κB, Nuclear factor κB, OVA, Ovalbumin, OX, Oxazolone, TLR, Toll-like receptor, WT, Wild-type

 

 Supported by the Atopic Dermatitis and Vaccinia Immunization Network; National Institutes of Health/National Institute of Allergy and Infectious Diseases contract NO1 (AI 40030); and a US Public Health Service grant AR-047417 to R.G. H.J. has received a postdoctoral fellowship from the American Heart Association.

 Disclosure of potential conflict of interest: H. Jin has received research support from the American Heart Association. H. Oettgen has served as a consultant and scientific advisor for Schering-Plough and as a consultant for Genentech and has received research support from Novartis. L. Gorelik is employed by Biogen Idec, Inc. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)00233-4

doi:10.1016/j.jaci.2009.02.007

The Journal of Allergy and Clinical Immunology
Volume 123, Issue 4 , Pages 875-882.e1, April 2009